Mössner, R; Schumacher, A; Kühn, K U; Cvetanovska, G; Rujescu, D; Zill, P; Quednow, B B; Rietschel, M; Wölwer, W; Gaebel, W; Wagner, M; Maier, W (2009). Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. Pharmacogenetics and Genomics, 19(1):91-94.
Full text not available from this repository.
View at publisher
The serotonin (5-HT) 1A receptor has been found to be dysregulated in prefrontal cortex and other brain regions in schizophrenia, and 5-HT1A receptor levels in the amygdala have been related to negative schizophrenia symptoms. We have assessed the impact of the functional C-1019G variant of the 5-HT1A receptor on the response to risperidone or haloperidol in a prospective, randomized, double-blind study. Patients were treated for 4 weeks and negative symptoms assessed weekly. The variant influenced the response to risperidone: improvement of negative symptoms by 4.38 points for carriers of the C allele, compared with the GG genotype (1.22 points, P=0.046). In a second independent study of 130 schizophrenia patients treated with atypical antipsychotics, this effect was confirmed (P=0.003). The functional variant of the 5-HT1A receptor thus influences the response of schizophrenia patients to atypical antipsychotics and may be useful in the future to predict the pharmacogenetics of negative symptoms.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > Psychiatric University Hospital Zurich > Clinic for Psychiatry, Psychotherapy, and Psychosomatics|
|DDC:||610 Medicine & health|
|Deposited On:||19 Nov 2008 08:27|
|Last Modified:||27 Nov 2013 20:33|
|Publisher:||Lippincott Wiliams & Wilkins|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page